Pulse.

a daily field guide to health research that matters

◆ Console

‹ Wed · 11 Nov 2026
Standard addition

CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study.

A novel antibody combination produces strong remission rates in blood cancers, opening options for people who didn't respond to prior treatments.

The trial evaluated a CD19-CD28 costimulatory bispecific antibody combined with glofitamab. The combination produced complete response rates of 42.4% in aggressive and 89.5% in indolent lymphoma, with cytokine release syndrome occurring in 53.8% of patients.

What the study was

Study design
Phase I dose-escalation clinical trial
Population
52 heavily pretreated patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Sample size
52
Category
Treatment Innovation
Maturity
Exploratory
Journal
Blood advances

Why it surfaced

The novel combination has promising early efficacy and pharmacodynamic evidence, but phase I size and nonrandomized design limit certainty

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.